LIG Biowise is an innovative biotechnology company developing an ultra-rapid, point-of-care (POC) diagnostic tests for infectious diseases. Its platform technology combines DNA extraction, amplification and detection into a single step. Initially targeting diagnostics for upper respiratory tract infections (URTIs), LIG Biowise is set to transform antibiotic prescribing practices and tackle antimicrobial resistance from its base in Manchester, UK.
LIG Biowise’s platform technology is an ultra-rapid POC diagnostic that tests for infectious diseases. Its novel technique combines DNA extraction, amplification and detection into a single step, resulting in faster diagnostic turn around, lower costs and higher precision. LIG Biowise is initially targeting upper respiratory tract infections (URTIs), with the intention to expand its technology across multiple areas of infectious disease diagnosis at the POC in both primary and secondary care. By offering a rapid, easy to use method for detecting infectious diseases, LIG Biowise’s technology can significantly reduce the time and costs of diagnosis by moving it from the lab bench to the POC in both primary and secondary care settings.
Showcase to 300+ investors and pharma at our 5th flagship LSX World Congress.
Plus save £500 before 14th December!
LSX is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.